ASBP
Aspire Biopharma Holdings, Inc.
There isn't enough reported data to score ASBP yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ASBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Strong |
ASBP's balance sheet is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its revenue.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ASBP PE Valuation
ASBP has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ASBP Forward outlook
There aren't enough analyst estimates for ASBP to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ASBP Earnings Per Share
ASBP and UNH do not have enough comparable growth data to identify a winner.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ASBP Quarterly Revenue
ASBP's revenue has grown year over year for four quarters in a row: $63,104 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4244% | N/A |
| Q1 2026 | -5806% | N/A |
| Q4 2025 | -43404% | N/A |
| Q3 2025 | -59016% | N/A |
UNH has the edge over ASBP on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ASBP on profitability, with a higher operating margin.
ASBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.1M | -$975.4K |
| Q1 2026 | -$3M | -$1.3M |
| Q4 2025 | -$927.8K | -220% |
| Q2 2025 | -$1.1M | -$548K |
| Q1 2025 | -$1.8M | +$508.5K |
| Q4 2024 | $772.1K | +$928.3K |
| Q2 2024 | -$592.3K | -$402.4K |
| Q1 2024 | -$2.3M | -$2.1M |
ASBP has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ASBP on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2415% | +997K shares |
| 1 year | +2447% | +997K shares |
ASBP has 1M diluted shares, up 2447% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | $13.8M |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $632,968 |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ASBP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ASBP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 0.0x | Very low |
| Q3 2023 | -0.0x | Very low |
| Q2 2023 | -0.1x | Net Cash |
| Q1 2023 | -0.2x | Net Cash |
ASBP's net debt is less than a year of its operating earnings (EBITDA).
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ASBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.4 | Oversold |
| Stochastic | 60.1 | Neutral |
ASBP's weekly RSI is 25 (oversold) and its Stochastic is 60 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ASBP PE vs Healthcare Sector
ASBP has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ASBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.45 | 0.6% below |
| 20 week MA | $7.92 | 6.1% above |
| 50 week MA | $30.4 | 72% below |
| 100 week MA | $1,485.1 | 99% below |
| 200 week MA | $7,335.9 | 100% below |
ASBP's trend is mixed: it's above one of its five weekly moving averages, and 100% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ASBP on trend strength, trading above more of its moving averages.
ASBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $12,000.0 | $12,372.0 | +3.1% |
| 2023 | $12,372.0 | $13,068.0 | +5.6% |
| 2024 | $13,068.0 | $13,800.0 | +5.6% |
| 2025 | $13,800.0 | $129.6 | -99% |
| 2026 YTD | $129.6 | $8.40 | -94% |
ASBP is down 94% so far in 2026, after finishing higher in three of the previous four years.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ASBP on returns for 2026, with the stronger performance.